Substance Use Disorder Management

Emergency Management

• In patients with altered mental status, seizures, arrhythmias, or toxidromal signs, positive benzoylecgonine may support diagnosis but should not delay emergency management, as recommended by the American Academy of Pediatrics 1

Non-Emergency Management

• For patients with cocaine-associated chest pain, high-risk patients (with ST-segment changes, elevated cardiac markers, recurrent pain, or hemodynamic instability) should be admitted to monitored beds, according to the American Heart Association 2
• Intermediate/low-risk patients with cocaine-associated chest pain can be safely managed in chest pain observation units for 9-12 hours, as suggested by the American Heart Association 2
• Approximately 0.7-6% of patients with cocaine-associated chest pain have myocardial infarction, as reported by the American Heart Association 2

Therapeutic Monitoring and Screening

• Positive benzoylecgonine results may guide treatment decisions in substance use disorder programs, as recommended by the American Academy of Pediatrics 1
• Results of adolescent screening for cocaine use should be interpreted as part of a comprehensive assessment, not in isolation, according to the American Academy of Pediatrics 1
• Cocaine is detected in approximately 32% of drug-facilitated sexual assault cases with unexpected positive toxicology, as reported by the American Academy of Pediatrics 3
• Urine tests detect benzoylecgonine, cocaine's primary metabolite, with a urinary half-life of 6-8 hours and a standard cutoff of 300 ng/mL, but lower cutoffs can extend detection time by up to 55% 2
• The mean time to first negative specimen for cocaine in urine is 43.6 ± 17.1 hours (range 16-66 hours), with a standard detection window of 1-3 days after last use, according to the American Heart Association and World Health Organization guidelines 2, 4

• Detection times can range from:

  Usage Pattern	Detection Time
  Single/Occasional Use	1-2 days
  Heavy, Chronic Use	up to 1-2 weeks

• Chronic, heavy users may have benzoylecgonine detected in urine for up to 22 days after last use, due to cocaine accumulation in deep body compartments and slow release back into circulation 2
• False negatives can occur due to testing outside the detection window, diluted samples, adulterated specimens, or cutoff concentration set too high, highlighting the importance of proper testing protocols 2, 1
• Self-reporting remains an important component of assessment, as negative tests don't rule out cocaine use if performed outside the detection window, as stated by the National Institute on Drug Abuse and American Heart Association 2
• Urine samples with creatinine between 2-20 mg/mL should be considered dilute and may miss substances present in lower concentrations, as reported by the American Academy of Pediatrics 1
• For the most reliable results when monitoring abstinence, testing should be conducted 2-3 days after last reported use for occasional users, and after at least 1-2 weeks for chronic users, with the understanding that some heavy users may require even longer periods of abstinence, according to the Substance Abuse and Mental Health Services Administration guidelines 2
• The American Academy of Pediatrics recommends considering the timing of the test relative to last reported use and extended monitoring for chronic users 1
• False-positive results are rare with confirmatory testing but can occur with some screening immunoassays due to cross-reactivity with certain medications, as reported by the American Academy of Pediatrics 1
• Healthcare providers should consider the limitations of urine testing and the potential for false-negative results when monitoring substance use, as recommended by the American Heart Association 2
• Dismissing patients based solely on test results could constitute patient abandonment, as stated by clinical guidelines from reputable sources, excluding Praxis Medical Insights 1
• The American Heart Association and other reputable sources emphasize the importance of considering the limitations of urine testing and the potential for false-negative results when monitoring substance use 2, 1